Clinical Trial Demonstrates High Response Rates
The TRANSCEND CLL 004 trial enrolled 117 adult patients across 20 U.S. sites between 2017 and 2022. All participants had relapsed or refractory disease and had received at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor. These targeted oral drugs had transformed care for CLL in recent years, but when they stop working or become intolerable, treatment options shrink sharply. The trial aimed to evaluate whether CAR-T therapy could offer a meaningful alternative.
Early findings from the study were published in The Lancet Oncology in January 2024. The primary endpoint was overall response rate as assessed by an independent review committee. Results showed an overall response rate of 83 percent, with a 95 percent confidence interval of 72 to 91. A complete remission, meaning no detectable cancer, was achieved in 20 percent of patients.
The durability of these responses stands out. With a median follow-up of 21.9 months, the median duration of response was 35.8 months. This suggests that for patients who respond, the benefit can be lasting. For those with relapsed or refractory CLL or SLL, few effective alternatives existed beyond experimental trials before this approval. CLL, a slow-growing cancer of the white blood cells that typically affects older adults, has long been treated with chemotherapy combined with immunotherapy, followed by Bruton tyrosine kinase inhibitors when needed. But for patients whose disease progresses despite those measures, CAR-T therapy now offers a chance at lasting remission.
Safety Profile and FDA Approval
As with any CAR-T therapy, side effects remain a concern that patients should discuss with their doctors. In the TRANSCEND CLL 004 trial, grade 3 or higher cytokine release syndrome occurred in 9 percent of patients, and grade 3 or higher neurotoxicity occurred in 12 percent of patients. These figures align with safety profiles seen in other CAR-T indications and underscore the need for careful patient selection and monitoring.
Based on these results, the FDA approved Breyanzi for this indication on March 15, 2024, making it the first CAR-T cell therapy approved for CLL and SLL. This milestone signals that the cellular immunotherapy revolution, once limited to a narrow set of leukemias and lymphomas, can reach a broader population living with a chronic and often relentless disease. CAR-T therapy represents a fundamentally different approach: a patient’s own immune cells are collected, genetically modified to recognize and attack cancer, then infused back into the body. The first CAR-T therapy won U.S. approval for acute lymphoblastic leukemia and certain lymphomas in 2017. Researchers have since worked to adapt the technology for other blood cancers, including CLL, which had proven especially resistant to earlier forms of immunotherapy.
This approval matters because it offers a durable response option for patients who have exhausted all standard therapies. CLL is defined as a chronic blood cancer in which the bone marrow produces too many abnormal lymphocytes that crowd out healthy blood cells and accumulate in the blood, lymph nodes, and spleen. While the disease often progresses slowly, it can be difficult to cure. For those whose CLL has relapsed after Bruton tyrosine kinase inhibitors and other treatments, CAR-T therapy provides a chance at lasting remission where few such chances existed before. The TRANSCEND CLL 004 trial provided the evidence needed for this regulatory decision, and ongoing follow-up will continue to inform doctors about long-term outcomes. Patients should always consult their healthcare team to understand whether this therapy is appropriate for their specific situation.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “CAR-T Therapy Shows High Response Rates in CLL Trial”, “description”: “Clinical Trial Demonstrates High Response Rates The TRANSCEND CLL 004 trial enrolled 117 adult patients across 20 U.S. sites between 2017 and 2022. All participants…”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Reza Karimi”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
